The Anesthetic That Crossed the Pacific and Made FDA History

The Numbers That Got FDA's Attention

Haisco's path to approval leaned on a multicenter, randomized, double-blind Phase 3 trial comparing cipepofol head-to-head against propofol in adults undergoing elective surgery. The primary goal was straightforward: prove that cipepofol could knock patients out just as reliably as propofol.

It did. 97.0% of cipepofol patients were successfully induced into general anesthesia, compared to 97.6% for propofol. The difference was a trivial -0.57 percentage points, well within the study's non-inferiority margin of -8%. In plain English: cipepofol works just as well.

But the safety data told the more interesting story.

Only 18% of cipepofol patients reported injection-site pain, versus 77.1% on propofol (p < 0.0001). That's not a marginal improvement; it's a transformation of the patient experience. The drug also showed milder drops in blood pressure and fewer respiratory side effects across clinical studies, though the composite safety endpoint in the pivotal trial was roughly similar between groups.

From Chengdu to the Operating Room

Haisco's journey with cipepofol started around 2012 in China, when its R&D team began tinkering with propofol's molecular structure. They introduced a chiral cyclopropyl group (a tiny three-carbon ring that changes how the molecule interacts with receptors) and ran thousands of screenings before landing on a winner.

The drug first earned approval from China's NMPA in December 2020, initially for sedation, general anesthesia, and ICU use. It has since been adopted by over 3,300 medical institutions in China, with more than 40 million patient visits under its belt. It's in Chinese medical textbooks. It's on the national reimbursement list. In China, cipepofol isn't novel anymore; it's mainstream.

The U.S. path was notably efficient. After getting FDA clearance for clinical trials in 2021, Haisco received a waiver to skip Phase 2 entirely and jump straight to pivotal Phase 3 studies. All U.S. clinical work wrapped up by 2024. The NDA was formally accepted in July 2025, and approval came roughly ten months later.

That Phase 2 waiver is worth pausing on. The FDA doesn't hand those out casually. It signals that existing international data (from Australia and China) was robust enough to justify going straight to the big confirmatory trial. For a China-originated drug in a high-risk therapeutic area, that's a meaningful vote of confidence.

Why This Matters Beyond One Drug

Propofol dominates roughly 35% of the broader anesthesia drug segment. Cipepofol's current FDA label is narrow: induction of general anesthesia in adults undergoing surgery. That's a slice, not the whole pie. In China, the drug is approved for maintenance of anesthesia, ICU sedation, pediatric use, and bronchoscopy sedation. Whether (and when) Haisco pursues those additional U.S. indications will determine how big this gets commercially.

But the business case is almost secondary to the symbolic weight. Chinese pharmaceutical companies have been licensing molecules to Western partners, filing INDs, and earning Fast Track designations for years. In 2024, Chinese firms received more than 30 FDA Fast Track designations. Tislelizumab (a PD-1 inhibitor) earned FDA approval that same year. The pipeline has been building.

Cipepofol is different because of context. Anesthesia isn't oncology, where novel mechanisms are almost expected. Putting someone under general anesthesia and trusting they'll wake up is about as high-stakes as medicine gets. The FDA essentially said: we trust this molecule, developed by a Chinese company, to safely render American patients unconscious on operating tables. That's not just regulatory approval. It's a credibility milestone.

What Comes Next

Haisco has signaled plans to seek European marketing approval, and a pediatric Phase 3b trial is underway in the U.S. with results expected around 2029. If cipepofol can replicate its adult success in children (where propofol's side effects are even more concerning), the commercial opportunity grows substantially.

For anesthesiologists, the pitch is simple: same knockout power, a fraction of the dose, and your patients won't wince when the drug hits their veins. For the broader industry, the message is harder to ignore. The era of pharmaceutical innovation flowing in only one direction? It's over.

Biogen Spent $5.6B on Apellis. Then It Torched the Science.

Biogen closed its $5.6 billion Apellis acquisition and immediately killed most of the company's research programs, keeping only the two products already making money. It's a pattern that keeps repeating in big pharma M&A, and it says a lot about what acquirers actually value.